返回 Agenda
Session 8C: Policy Updates: Staying Informed and Understanding Their Potential Impact to the Medical Liaison Role
Session Chair(s)
Ed Cunningham, PharmD
Sunovion Pharmaceuticals, Inc., United States
With the rapidly-changing political and health care landscape in the US, the environment manufacturers operate in is likely to increase in complexity. Medical Liaisons play a critical role in the exchange of scientific information with health care professionals, and the regulation of those communications remains in a state of flux. This session will provide an update on current legislative, judicial and regulatory developments, and their potential implications to the Medical Liaison role. A summary of the recent discussions related to the FDA’s hearing on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products, among other topics, will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe and discuss current policies regulating medical liaison communications
- Explore recent updates and trends in order to better prepare and react to changes as they evolve
Speaker(s)
Recent Developments Impacting the Ability to Communicate Truthful, Non-Misleading Information
Torrey Cope, JD
Sidley Austin LLP, United States
Partner
Industry Perspective
Jamie Haney, JD
Eli Lilly and Company, United States
General Cousel - Lilly Diabetes Senior Director and Assistant General Counsel
Panel Discussion
All Session Speakers, United States